

Supporting information

Effect of piperine co-delivery on the oral bioavailability of cannabidiol: Insights from *in vitro* digestion and *in vivo* pharmacokinetics

Renata Vardanega^{1,2*}, Fernanda L. Lüdtkke^{1,2}, Luis Loureiro^{1,2}, Andrea Fernández-Carrera³,
Joana Santos¹, Armando Venâncio^{1,2}, Ana C. Pinheiro^{1,2}, África González-Fernández^{4,5},
António A. Vicente^{1,2}

¹Centre of Biological Engineering, University of Minho, Braga, 4710-057, Portugal.

²LABBELS - Associate Laboratory, Guimarães, 4800-058, Portugal.

³CINBIO, University of Vigo, Vigo, 36310, Spain.

⁴CINBIO, Immunology group, University of Vigo, Vigo, 36310, Spain.

⁵Immunology, Instituto de Investigación Sanitaria Galicia Sur (IIS-GS), SERGAS-UVIGO, Vigo, 36312, Spain.

*Corresponding author: renata.vardanega@ceb.uminho.pt + 351 253 601 962

Table S1: Composition (mmol/L) of simulated digestive fluids according to recommended by Brodkorb et al. [*Nature Protocols*, 14, (2019) p. 991–1014].

Salt	Simulated salivary fluid (SSF)	Simulated gastric fluid (SGF)	Simulated intestinal fluid (SIF)
KCl	15.1	6.9	6.8
KH ₂ PO ₄	3.7	0.9	0.8
NaHCO ₃	13.6	25.0	85.0
NaCl	-	47.2	38.4
MgCl ₂ (H ₂ O) ₆	0.15	0.12	0.33
(NH ₄) ₂ CO ₃	0.06	0.5	-
CaCl ₂ (H ₂ O) ₂	1.5	0.15	0.6

Table S2: Protocol for blood collection via mandibular vein.

	Mice code									
Collection time (h)	1	2	3	4	5	6	7	8	9	10
0										
0.5										
1										
2										
3										
4 (cardiac punch)										
6 (cardiac punch)										

Table S3: Entrapment efficiency of PIP into the NLCs during 28 days of storage at 4 °C.

Sample	Day 0	14 days	28 days
NLC-PIP-CBD _{ext}	99.7 ± 0.3	99.80 ± 0.03	99.80 ± 0.01
NLC-PIP-CBD _{iso}	99.7 ± 0.2	99.82 ± 0.02	99.80 ± 0.01